Drug Trial Radar · NCT03611868
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Aug 29, 2018
Primary completion
Dec 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Aug 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.
Conditions
- Unresectable or Metastatic Melanoma or Advanced Solid Tumors
- Melanoma
- Uveal Melanoma
- P53 Mutation
- MDM2 Gene Mutation
- Cutaneous Melanoma
- Mucosal Melanoma
- Malignant Peripheral Nerve Sheath Tumors (MPNST)
Interventions
Phase 1b: APG-115+pembrolizumabDrug
dose escalation of APG-115 in combination with label dose of pembrolizumab, Four dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrateddose escalation of APG-115 in combination with label dose of pembrolizumab, Fourfour dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as there are cycles every 3-weeks a cycle. Pembrolizumab is administrated following FDA approved label dose, i.e., 200 mg intravenous infusion at Day 1 of every 3 weeks as a cycle. Phase II: Combination of APG-115 at 150 mg (RP2D) and pembrolizumab or APG-115 monotherapy alone.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated DoseTime frame: 21 days
- Recommended Phase II DoseTime frame: 21 days
- Overall Response RateTime frame: up to 12 months
Locations
21 sites in 2 countries. Site status is shown where the registry gives one.
University of Arizona Cancer Center
Tucson, Arizona
Highlands Oncology
Rogers, Arkansas
UCLA Hematology & Oncology Clinic
Los Angeles, California
Sarcoma Oncology Research Center
Santa Monica, California
Children's National Research Institute
Washington D.C., District of Columbia
Sarah Cannon/FCSRI
Fort Myers, Florida
Washington University School of Medicine
St Louis, Missouri
Memorial Sloan Kettering
New York, New York
Duke Cancer Institute
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Penn State Hershey Medical Center Cancer Institute
Hershey, Pennsylvania
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Sarah Cannon Cancer Center
Nashville, Tennessee
University of Texas MD Anderson Cancer Center
Houston, Texas
Next Oncology
San Antonio, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Metro South Hospital and Health Services via Princess Alexandra Hospital
Brisbane, Queensland, Australia
Queensland Children's Hospital
South Brisbane, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Austin Health
Heidelberg, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.